entertainment -WSS

entertainment

author：focus 2025-10-01 17:56:50 - browse：61278

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Deliver public health messages at the right time

focus

WSS

Most antidepressants don't work on kids, teens, study finds

Sepsis can kill a child within hours. Here's how hospitals are fighting back

FDA proposes changes to key medical devices approval pathway

WATCH: Why do bright lights make us see spots?

Private equity could exacerbate cardiology's overuse problem, experts fear

The creative science of coining drug names

hotspot

entertainment

hotspot

Psychedelics group wrestles with new pharma identity

Can gargling with Listerine treat gonorrhea of the mouth?

Trump demands the U.S. pay no more for drugs than other countries … again

Deliver public health messages at the right time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Brain technologies pose threats that are all too real, experts warn

United colonoscopy coverage change 'may cost lives,' doctors say

Class action alleges UnitedHealth concealed DOJ probe

In age of alternative facts, a scholarly course on calling out crap

Warren pushes Witty on UnitedHealth's control over physicians

leisure time

Lawmakers grill UnitedHealth CEO on Change cyberattack

Food makers to regulators: Ultra

PEPFAR is under serious threat — and so is global health

Regeneron agrees to White House price limits on anti

Food makers tried to stack nutrition panel with preferred experts

Private equity could exacerbate cardiology's overuse problem, experts fear

focus

leisure time

focus

hotspot